Dyne Spikes as Phase 3 Duchenne Trial Launch Strengthens Path Toward Potential 2027 Approval

2026-05-25 18:56:40 ET

Dyne Therapeutics ( DYN) traded higher Wednesday after the company announced the initiation of its Phase 3 FORZETTO trial for zeleciment rostudirsen, also known as z-rostudirsen or DYNE-251, in Duchenne muscular dystrophy patients amenable to exon 51 skipping. Seeking Alpha noted the stock moved up as the late-stage trial officially got underway. ( Seeking Alpha )

Key Takeaways

• Dyne has started the Phase 3 FORZETTO trial for z-rostudirsen in Duchenne muscular dystrophy.
• The first trial site is open for enrollment, turning the program from a regulatory plan into an active late-stage study.
• FORZETTO will enroll about 90 ambulatory male patients ages 4 to 18 with DMD mutations amenable to exon 51 skipping.
• The trial will run for 72 weeks, with patients randomized 1:1 to z-rostudirsen or placebo every four weeks.
• The primary endpoint is rise from floor velocity, also known as time to rise velocity, at Week 73.
• Dyne says the trial design and protocol are aligned with the FDA.
• The company still plans to submit a BLA for U.S. accelerated approval in Q2 2026, with a potential U.S. launch in Q1 2027 if Priority Review is granted and the drug is approved.

This is not a new data readout, which is an important distinction for investors. The stock reaction is about execution and regulatory progress, not fresh efficacy results. Dyne already had the key Phase 1/2 DELIVER data in hand. Now the company is showing that it can move the program into the confirmatory stage while preparing its U.S. accelerated approval filing.

The earlier DELIVER data are the foundation of the bull case. In December, Dyne said the registrational expansion cohort of DELIVER met its primary endpoint, with muscle-content-adjusted dystrophin expression rising to 5.46% of normal at six months, with a p-value below 0.0001. The company also reported functional improvement across multiple clinical endpoints and said lung function was preserved at six months compared with a decline in placebo.

The functional signal is why FORZETTO matters so much. In the DELIVER registrational expansion cohort, patients treated with z-rostudirsen 20 mg/kg every four weeks showed improvement in rise from floor velocity at six months versus pooled placebo, with a nominal p-value below 0.05. Dyne said that improvement exceeded a published minimal clinically important difference, although the company also noted the functional analysis was post-hoc and not part of a formal statistical testing plan for functional endpoints.

Safety remains another key part of the thesis. In previously reported DELIVER safety data from 86 participants followed for up to 36 months, Dyne said z-rostudirsen showed a favorable safety profile, with most related treatment-emergent adverse events classified as mild or moderate. The most common related events were fever and headache, and no related serious adverse events were seen in the registrational expansion cohort.

The bigger strategic story is that Dyne is trying to build a DMD franchise, not just a single exon 51 drug. In addition to z-rostudirsen, the company is advancing preclinical candidates for DMD mutations amenable to skipping exons 53, 45, 44, and 55. That matters because exon 51 is only one slice of the DMD population, while a broader exon-skipping portfolio could expand Dyne's commercial opportunity over time.

The balance sheet also gives the company room to execute. Dyne reported $972.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and said that funding should support operations into the first quarter of 2028. The company reported a Q1 net loss of $120.9 million, reflecting the cost of late-stage development and launch preparation.

The post Dyne Spikes as Phase 3 Duchenne Trial Launch Strengthens Path Toward Potential 2027 Approval appeared first on PRISM MarketView .

COMTEX_481809254/2927/2026-05-25T17:56:40